Kineta: ; (ii) The Unaudited Interim Consolidated Financial Information Of Kineta As Of September 30, 2022 And For Each Of The Nine Months Ended September 30, 2022 And 2021 Referred To In Item 9.01(a) Below; And (iii) The Unaudited Pro Forma Condensed Combined Financial Information As Of September 30, 2022 And For The Nine Months Ended September 30, 2022 And For The Year Ended December 31, 2021, Referred To In Item 9.01(b) Below, Completion Of Acquisition Or Disposition Of Assets, Unregistered Sales Of Equity Securities, Material Modification To Rights Of Security Holders, Changes In Registrant S Certifying Accountant, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Kineta, Inc. (formerly Yumanity Therapeutics Inc; Proteostasis Therapeutics Inc)
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***